Unum Therapeutics Inc. | 200 Cambridge Park Drive Suite 3100 | Cambridge, MA 02140  USA

Tel. +1.617.945.5576 | Email: info@unumrx.com

  • LinkedIn - White Circle
  • Twitter - White Circle

© Copyright 2014-2019 Unum Therapeutics

Unum’s leadership possesses biotech and large pharma drug development experience and deep scientific expertise in cancer immunotherapy. It includes pioneers in the field who created the CAR-T approach now pursued by several companies and those who led the first large pharma effort to develop such therapies.

 

 

Charles "Chuck" Wilson, PhD

President & CEO

Bio

 

 

Seth Ettenberg, PhD

Chief Scientific Officer

Bio

 

Christiana Stamoulis

Chief Financial Officer and Head of Corporate Development

Bio

 

Geoffrey Hodge

Senior Vice President, Operations

Bio

 

Michael Vasconcelles, MD

Chief Medical Officer

Bio

 

Dario Campana, MD, PhD

Scientific Founder

Bio

Dario Campana, MD, PhD

Scientific Founder
 

Dario is the scientific founder of the company, and a leader in the field of cancer cell therapies. At the National University of Singapore (NUS), Dario developed the ACTR technology that forms the basis for Unum. At St. Jude Children’s Research Hospital, he created the CD19 chimeric antigen receptor (CAR) that was subsequently shown to be highly effective in treating patients with Acute Lymphoblastic Leukemia (ALL), an aggressive form of the disease. He has extensive experience managing clinical cell therapy trials in oncology. He received his MD from the University of Torino and his PhD from the University of Milan.